Workshop on Clinical Translation

Stem Cells: Model, Target, & Therapy

Tuesday, 23 June 2020

Stem cells can drive clinical development in a diversity of ways. Stem cells can help identify new therapeutics through disease modeling, drug screening, and personalized medicine. Endogenous stem cells can be the targets of therapeutics, which can stimulate regeneration in vivo. Finally, stem cells or stem cell-derived products can be the therapeutic themselves, delivered to patients to replace or repair damaged tissues. The ISSCR’s Workshop on Clinical Translation will showcase speakers from academia and industry who will discuss various approaches to develop cellular therapies in this translationally-focused program. This year’s workshop explores the broad ways that stem cells are advancing pre-clinical research and clinical trials in three sessions:

Modeling Stem Cells for Discovery
Endogenous Stem Cells as Targets
Stem Cells as Drugs in Clinical Trials

The Workshop on Clinical Translation is a full-day program designed for scientists, physicians, physician-scientists, and those interested in the latest clinical applications of stem cell research. A renowned panel of speakers will cover a range of topics from pre-clinical modeling to ongoing clinical trials.

Date: 23 June, 2020
Time: TBD
Where: Online

Registration: Included with ISSCR 2020 Annual Meeting registration

Tentative Speakers + Topics

WELCOME | OPENING REMARKS

[ Welcome to the Workshop on Clinical Translation. ]

RUBIN_Lee_copyright_Harvard_2017_credit_Kris_Snibbe-Harvard-University

[Program Committee]
Lee Rubin, PhD
Harvard University, USA

SESSION 1 | MODELING STEM CELLS FOR DISCOVERY

[ Disease modeling, therapeutic screening, and advanced approaches including the genetics of disease and personalized medicine. ]

EFBCCTWR-Presenter-DolmetschR

[Program Committee + Moderator]
Ricardo Dolmetsch, PhD
Novartis, USA

Giorgia-Quadrato-1000

Giorgia Quadrato, PhD
University of Southern California, Keck School of Medicine, USA

Woolf_01

Clifford Woolf, MD, PhD
Boston Children's Hospital, USA

Ronald Li_headshot 1

Ronald Li, PhD
Karolinska Institutet, Sweden/Hong Kong
NovoHeart, Canada

Kaykas picture

Ajamete Kaykas, PhD
Insitro, USA

SESSION 2 | ENDOGENOUS STEM CELLS AS TARGETS

[ Drugs that target endogenous stem cells for therapeutic purposes.]

141201_Chee-Yeun Chung

[Program Committee + Moderator]
Chee-Yeun Chung, PhD
Yumanity, USA

Accili 2012 300dpi

Domenico Accili, MD
Columbia Universiry, USA

Hua portrait

Hua Lin, PhD
Forkhead Biotherapeutics, USA

McGuigan-Alison

Alison McGuigan, PhD
University of Toronto, Canada

Edge-Albert

Albert Edge, PhD
Massachusetts Eye and Ear, USA; Decibel Therapeutics, USA

SESSION 3 | STEM CELLS AS DRUGS

[ What is at the cutting edge and what is the future of cell and gene therapy. ]

[Program Committee + Moderator]
Jerome Ritz, MD
Dana Farber Cancer Institute, USA

Williams

David Williams, MD
Boston Children's Hospital, USA

Kirkeby

Agnete Kirkeby, PhD
University of Copenhagen, Denmark
Lund University, Sweden

Sonja Schrepfer, MD, PhD
University of California, San Francisco, USA

[ All sessions will conclude with a panel discussion between the speakers and the moderator. ]

WRAP UP | CLOSING REMARKS

[ Where the clinical translation of stem cells is and where it is going. ]

Stacie Weninger FPrime website

[Program Committee]
Stacie Weninger, PhD
F-Prime Capital, USA

Who Should Attend?

This program is designed for scientists, physicians, physician-scientists, and those interested in the latest clinical applications of stem cell research.